WILL THIS TRIAL CHANGE MY PRACTICE? | Proceedings of

Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications

EuroIntervention 2018;14:e598-e602 published online ahead of print July 2018 published online e-edition August 2018. DOI: 10.4244/EIJY18M07_1

Sebastian Ewen1*, MD; Lucas Lauder1; Michel Azizi2,3, MD; David E. Kandzari4, MD; Atul Pathak5, MD, PhD; Faisal Sharif6, MD, PhD; William Wijns7,8, MD, PhD; Felix Mahfoud1, MD; Thomas F. Lüscher8,9, MD

1. Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany; 2. Paris-Descartes University, Paris, France; 3. Assistance Publique-Hôpitaux de Paris, Hôpital Europ

Introduction to the session

The aim of this summary report is to capture the content of the session at EuroPCR 2018 that reviewed the implications for clinical practice of the SPYRAL HTN-ON MED study1, in order to share the critical analysis of the trial and report the views expressed in the interactive discussion. This article does not constitute an independent review of the topic by the authors.

What was known before SPYRAL HTN-ON MED?

Hypertension is highly prevalent around the world and is associated with cardiovascular morbidity and death. However, blood pressure (BP) control remains unacceptably low ...

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Share on Facebook Share on Twitter Share on Linkedin